HD Biosciences Co., Ltd (HDB) and Anchor Therapeutics, Inc. today announced that they have formed a strategic collaboration to co-develop and co-market Anchor¡¯s proprietary pepducin technology and provide novel drug development solutions to global pharmaceutical companies with drug discovery efforts focused on G-protein coupled receptors (GPCR).
HD Biosciences Co., a leader in plate-based pharmacology and biology focused contract research organization (CRO), announced that the company¡¯s HTS and SAR platforms achieved 5 million data points from the services provided to pharmaceutical and biotech partners.
HD Biosciences announces the full implementation of target identification & validation platform which won a major agreement with its partner on Adeno-Associated Virus (AAVs) based technology application on drug discovery. The agreement is focused on isogenic human disease models and sequential pharmacology research which will assist client in their decision on portfolio development.
HD Biosciences, a leading biology-focused contract research organization (CRO) in Shanghai, has celebrated her 10th anniversary in the beautiful Golden October of 2012 at a five star Huang Shan Smoky Willow Resort recently. The company was established in October 2002, first as a TCM based drug discovery company.
HD Biosciences Co. Ltd. (HDB), recently has completed the renovation of another state-of-the art facility in its Zhangjiang High Tech Park (East) campus. The new R&D facility, which is adjacent to its current site, has approximately 30,000 square feet of laboratory space including a bio-safety level-2 in vivo pharmacology center, will add significant capacities in R&D to support growing needs from clients.
HD Biosciences, a leading biology focused contract research organization (CRO), continues strengthening its leadership in plate based pharmacology. The company recently inked an agreement to form a strategic collaboration with a major pharmaceutical company to build a HTS/Hit Identification center to support the pharmaceutical company¡¯s efforts in new lead discovery.